» Articles » PMID: 27256139

Interactions Between Amiodarone and the HERG Potassium Channel Pore Determined with Mutagenesis and in Silico Docking

Overview
Date 2016 Jun 4
PMID 27256139
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The antiarrhythmic drug amiodarone delays cardiac repolarisation through inhibition of hERG-encoded potassium channels responsible for the rapid delayed rectifier potassium current (IKr). This study aimed to elucidate molecular determinants of amiodarone binding to the hERG channel. Whole-cell patch-clamp recordings were made at 37°C of ionic current (IhERG) carried by wild-type (WT) or mutant hERG channels expressed in HEK293 cells. Alanine mutagenesis and ligand docking were used to investigate the roles of pore cavity amino-acid residues in amiodarone binding. Amiodarone inhibited WT outward IhERG tails with a half-maximal inhibitory concentration (IC50) of ∼45nM, whilst inward IhERG tails in a high K(+) external solution ([K(+)]e) of 94mM were blocked with an IC50 of 117.8nM. Amiodarone's inhibitory action was contingent upon channel gating. Alanine-mutagenesis identified multiple residues directly or indirectly involved in amiodarone binding. The IC50 for the S6 aromatic Y652A mutation was increased to ∼20-fold that of WT IhERG, similar to the pore helical mutant S624A (∼22-fold WT control). The IC50 for F656A mutant IhERG was ∼17-fold its corresponding WT control. Computational docking using a MthK-based hERG model differentiated residues likely to interact directly with drug and those whose Ala mutation may affect drug block allosterically. The requirements for amiodarone block of aromatic residues F656 and Y652 within the hERG pore cavity are smaller than for other high affinity IhERG inhibitors, with relative importance to amiodarone binding of the residues investigated being S624A∼Y652A>F656A>V659A>G648A>T623A.

Citing Articles

Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.

Zhang Y, El Harchi A, James A, Oiki S, Dempsey C, Hancox J Cell Mol Life Sci. 2024; 81(1):466.

PMID: 39607488 PMC: 11604869. DOI: 10.1007/s00018-024-05498-4.


Calculations of the binding free energies of the Comprehensive Proarrhythmia Assay (CiPA) reference drugs to cardiac ion channels.

Negami T, Terada T Biophys Physicobiol. 2024; 20(2):e200016.

PMID: 38496247 PMC: 10941965. DOI: 10.2142/biophysico.bppb-v20.0016.


Harnessing AlphaFold to reveal hERG channel conformational state secrets.

Ngo K, Yang P, Yarov-Yarovoy V, Clancy C, Vorobyov I bioRxiv. 2024; .

PMID: 38352360 PMC: 10862728. DOI: 10.1101/2024.01.27.577468.


Amiodarone Advances the Apoptosis of Cardiomyocytes by Repressing Sigmar1 Expression and Blocking KCNH2-related Potassium Channels.

Liang H, Li H, Li F, Xiong X, Gao Y Curr Mol Med. 2024; 25(1):69-78.

PMID: 38204277 DOI: 10.2174/0115665240265771231129105108.


Structural modeling of hERG channel-drug interactions using Rosetta.

Emigh Cortez A, DeMarco K, Furutani K, Bekker S, Sack J, Wulff H Front Pharmacol. 2023; 14:1244166.

PMID: 38035013 PMC: 10682396. DOI: 10.3389/fphar.2023.1244166.


References
1.
El Harchi A, Zhang Y, Hussein L, Dempsey C, Hancox J . Molecular determinants of hERG potassium channel inhibition by disopyramide. J Mol Cell Cardiol. 2011; 52(1):185-95. DOI: 10.1016/j.yjmcc.2011.09.021. View

2.
Du C, Zhang Y, El Harchi A, Dempsey C, Hancox J . Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants. J Mol Cell Cardiol. 2014; 74:220-30. PMC: 4121676. DOI: 10.1016/j.yjmcc.2014.05.013. View

3.
Kannan R, Nademanee K, Hendrickson J, Rostami H, Singh B . Amiodarone kinetics after oral doses. Clin Pharmacol Ther. 1982; 31(4):438-44. DOI: 10.1038/clpt.1982.57. View

4.
Dempsey C, Wright D, Colenso C, Sessions R, Hancox J . Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block. J Chem Inf Model. 2014; 54(2):601-12. PMC: 3977586. DOI: 10.1021/ci400707h. View

5.
Sanguinetti M, Mitcheson J . Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci. 2005; 26(3):119-24. DOI: 10.1016/j.tips.2005.01.003. View